Aortic Valve Replacement With the St. Jude Medical Prosthesis and Fixed Dose Anticoagulation

• Published in: Journal of cardiac surgery Vol. 12; no. 6; pp. 363 - 370
• Main Authors: Katircioglu, S. Fehmi, Yamak, Birol, Ulus, A. Tulga, Iscan, H. Zafer, Mavitas, Binali, Tasdemir, Oguz
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.11.1997
• Subjects: Adolescent; Adult; Aged; Anticoagulants - administration & dosage; Aortic Valve; Aspirin - administration & dosage; Child; Dipyridamole - administration & dosage; Drug Therapy, Combination; Female; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation - mortality; Hemorrhage - chemically induced; Humans; Male; Middle Aged; Partial Thromboplastin Time; Platelet Aggregation Inhibitors - administration & dosage; Postoperative Complications - mortality; Postoperative Complications - prevention & control; Prosthesis Design; Reoperation - statistics & numerical data; Survival Analysis; Thromboembolism - prevention & control; Warfarin - administration & dosage
• ISSN: 0886-0440; 1540-8191
• DOI: 10.1111/j.1540-8191.1997.tb00152.x

Over a 10‐year period, between 1986 and 1996, 865 patients underwent primary aortic valve replacement (AVR) with the St. Jude Medical mechanical prosthesis. Patients who had undergone valve replacement with a different type of prosthesis previously were excluded from this study. Patient age ranged from 11 to 79 years. The mean age was 42.9 ± 14.54. The gender distribution was 396 men (45.8%) and 469 women (54.2%). All patients received 2.5 mg/day Coumadin after extubation. A combination of the antiagregant therapy (Dypridamole 3 × 75 mg/day, Asprine 100 mg/day) was added after removal of the chest tubes. The dosage of Coumadin was maintained constant regardless of the prothrombin time (PT) or cardiac rhythm. There were 101 valve‐related complications (4.2% per patient year [ppy]) occurring in the late follow‐up period. Of these complications; 38 were anticoagulant‐related hemorrhage (1.58% ppy), 3 were paravalvular leak (0.12% ppy), and 36 were thromboembolism (1.4% ppy). There were 24 reoperations (0.99% ppy) and 17 late deaths. The linearized late mortality rate was 0.7% ppy. Long‐term survival estimates at 5 and 10 years were 97.14 ± 0.82% and 94.86 ± 1.54%, respectively. We conclude from the data that the St. Jude Medical valve may allow the use of a low level of anticoagulation. This study shows that fixed dose oral anticoagulation does not increase the rate of thromboembolism in patients with the St. Jude aortic valve. This protocol does not result in reduction of bleeding complications, however.